Related Experiment Videos
Ganglioside treatment of genetic and alloxan-induced diabetic neuropathy
Abstract:
Peripheral neuropathy is a common complication of diabetes. Using the mutant diabetic mouse C57BL/ks (db/db) and alloxan-treated rats, 30 days after intoxication, we investigated development and treatment with gangliosides of such a disease. The db/db mouse develops a neuropathy characterized by a loss in conduction velocity shown as early as 80-90 days after birth and maintained throughout life. At later stages (5-6 months of age) there is a drop in slow transport and myelin particle density. These changes are correlated by a lack of response to insulin treatment, which, prior to this stage, is capable of improving nerve conduction velocity (NCV). On the other hand gangliosides became effective, improving NCV, myelin particle density and sensory perception (auditory deficit) at 5 months of age in the db/db mouse. We presume that this differential neuronal response to insulin and gangliosides indicates a change of the neuropathy from a metabolic stage to neuronal. Alloxan induced diabetic neuropathy is treatable with gangliosides even 30 days after intoxication.
Insights
Gangliosides effectively treat diabetic neuropathy in mice and rats, improving nerve function and sensory perception even at later disease stages. This suggests gangliosides offer a therapeutic advantage over insulin when neuropathy progresses.
Area of Science:
- Neuroscience
- Diabetology
- Pharmacology
Background:
- Diabetic peripheral neuropathy is a common and debilitating complication of diabetes mellitus.
- Early stages may respond to metabolic control, but advanced neuropathy often shows limited response to insulin.
- Understanding the progression and therapeutic targets is crucial for effective treatment.
Purpose of the Study:
- To investigate the development of diabetic peripheral neuropathy in mouse and rat models.
- To evaluate the efficacy of ganglioside treatment in different stages of diabetic neuropathy.
- To compare the therapeutic effects of gangliosides and insulin.
Main Methods:
- Utilized mutant diabetic mice (C57BL/ks db/db) and alloxan-induced diabetic rats.
- Assessed nerve conduction velocity (NCV), slow axonal transport, and myelin particle density.
- Administered insulin and gangliosides at various time points post-diabetes induction.
Main Results:
- Db/db mice showed reduced NCV early on, with impaired slow transport and myelin density later.
- Insulin improved NCV in early stages but lost efficacy in advanced neuropathy.
- Gangliosides improved NCV, myelin density, and auditory function in advanced diabetic neuropathy.
Conclusions:
- Diabetic neuropathy progression involves a shift from a metabolic to a neuronal stage.
- Gangliosides demonstrate therapeutic efficacy in advanced diabetic neuropathy where insulin is less effective.
- Gangliosides represent a promising treatment for diabetic peripheral neuropathy, particularly in later stages.